Celgene 's (Nasdaq: CELG) fourth-quarter earnings tend to be anticlamatic since the drugmaker traditionally releases preliminary figures at the annual JPMorgan conference in January. Still, the earnings call is still a good chance for investors to hear what management has to say, and this year was no different. As you'll recall, Celgene's shares declined substantially after the company said that Abraxane hadn't extended progression-free survival in lung cancer patients.